Compound: Levodropropizine
SMILES: O[C@H](CO)CN1CCN(c2ccccc2)CC1
InChIKey: PTVWPYVOOKLBCG-ZDUSSCGKSA-N
Synonyms: Levodropropizine, 99291-25-5, Levotuss, Danka, (-)-Dropropizine, Levdropropizine, (S)-(-)-Dropropizine, Rapitux, Levodropropizina, Levodropropizinum, Levopront, L-dropropizine, Dropropizine, (s)-, 3O31P6T4G3, (-)-(S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol, DTXSID8023210, CHEBI:82722, Levdropropizina, dipropizine, (S)-, RefChem:153202, DTXCID003210, R05DB27, (S)-3-(4-Phenylpiperazin-1-yl)propane-1,2-diol, (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol, MFCD00866852, Levodropropizine [INN], dipropizine, (S)-isomer, (s)-3-(4-phenyl-1-piperazinyl)-1,2-propanediol, 1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (2S)-, Levodropropizine (INN), Dropropizine S-form, Levodropropizinum [INN-Latin], Levodropropizina [INN-Spanish], DF 526, Levodropropizine [INN:BAN], Salvituss, UNII-3O31P6T4G3, Levopront (TN), CAS-17692-31-8, Levodropropizine CRS, S(-)-3-(4-Phenylpiperazin-1-yl)propane-1,2-diol, LVDP, GlyTouCan:G01710KR, Levodropropizine impurity A, Levodropropizine (Standard), SCHEMBL29043, orb1310823, CHEMBL1288810, LEVODROPROPIZINE [MART.], HY-B1895R, (2S)-3-(4-PHENYL-1-PIPERAZINYL)-1,2-PROPANEDIOL, 1,2-Propanediol, 3-(4-phenylpiperazin-1-yl)-, S(-)-, DROPROPIZINE S-FORM [MI], LEVODROPROPIZINE [WHO-DD], HMS3885B07, G01710KR, HY-B1895, BBL036696, EBC-03709, s4131, STL559075, AKOS015889397, AC-2084, AC-8088, CCG-266840, CS-5212, DB12472, FP31559, LEVODROPROPIZINE [EP MONOGRAPH], NCGC00016730-01, NCGC00018230-01, NCGC00018230-06, AS-12822, SY237559, L0339, NS00096429, D08119, F15098, EN300-1718684, AO-022/43512153, F211612, Q408131, BRD-K83551379-001-01-8, BRD-K83551379-001-02-6, S-(-)-3-(4-Phenylpiperazin-1-yl)propane-1,2-diol, Z301111588, 1,2-PROPANEDIOL, 3-(4-PHENYL-1-PIPERAZINYL)-, (S)-
Theoretical properties:
molecular_formula: C13H20N2O2
molecular_weight: 236.31 g/mol
exact_mass: 236.152477885 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 4
heavy_atom_count: 17
topological_polar_surface_area: 46.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Levodropropizine is a member of the class of N-arylpiperazines that is N-phenylpiperazine in which the amino hydrogen is replaced by a 2,3-dihydroxypropyl group (the S-enantiomer). A peripherally acting antitussive drug that is used as an alternative to opioids. It has a role as an antitussive. It is a secondary alcohol, a N-alkylpiperazine and a N-arylpiperazine.
chebi: A member of the class of <em>N</em>-arylpiperazines that is <em>N</em>-phenylpiperazine in which the amino hydrogen is replaced by a 2,3-dihydroxypropyl group (the <i>S</i>-enantiomer). A peripherally acting antitussive drug that is used as an alternative to opioids.
chembl: LEVODROPROPIZINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Levodropropizine is a cough suppressant. It is the levo isomer of dropropizine. It acts as a peripheral antitussive, with no action in the central nervous system. It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.

In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as patent infringement protection for its 2017 registered antitussive drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine." In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its mucoactive drug, Levotics CR Tab (levodropropizine).